BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30848394)

  • 21. [Advances in the treatment of chronic lymphocytic leukaemia].
    Mozas P; Delgado J
    Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
    Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
    Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexistence of myelodysplastic syndrome and untreated chronic lymphocytic leukemia with development of acute myeloid leukemia immediately after treatment of chronic lymphocytic leukemia.
    Bracey AW; Maddox AM; Immken L; Hsu SM; Marks ME
    Am J Hematol; 1989 Mar; 30(3):174-80. PubMed ID: 2916561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.
    Korycka-Wołowiec A; Wołowiec D; Robak T
    Expert Opin Drug Saf; 2017 Feb; 16(2):185-201. PubMed ID: 27880061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Connection between Parameters of Erythron System and Myelofibrosis during Chronic Myeloleukemia, Multiply Mieloma, and Chronic Lymphatic Leukemia.
    Dolgikh TY; Sholenberg EV; Kachesov IV; Senchukova SR
    Bull Exp Biol Med; 2018 Jan; 164(3):382-385. PubMed ID: 29308562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.
    Sandhu S; Mulligan SP
    Haematologica; 2015 Apr; 100(4):411-4. PubMed ID: 25828085
    [No Abstract]   [Full Text] [Related]  

  • 33. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
    Olin JL; Griffiths CL; Smith MB
    J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoimmunotherapy of chronic lymphocytic leukemia.
    Tam CS; Keating MJ
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):479-98. PubMed ID: 17707835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ
    J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advances in the treatment of chronic lymphocytic leukaemia].
    Obrtlíková P; Trněný M
    Vnitr Lek; 2013 Jul; 59(7):632-4. PubMed ID: 23909273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment approaches in CLL: Challenges and opportunities in the elderly.
    Eichhorst B; Hallek M; Goede V
    J Geriatr Oncol; 2016 Sep; 7(5):375-82. PubMed ID: 27491497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.
    Wang Z; Zhang Y; Liu H; Salati E; Chiriva-Internati M; Lim SH
    Blood; 2003 Feb; 101(3):955-60. PubMed ID: 12393489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.